Also, in addition to CG400549 and NDM-1 programs, our capability in discovery and development of anti-infective drugs had been validated in 2010 when we announced that we had entered into R&D collaboration with AstraZeneca in the area of novel anti-infectives and it was the first time that AstraZeneca had entered into such agreement with a Korean biotech company.

While it certainly is challenging to discover and develop totally novel class of antibiotics, we always take pride in our work, as our drug candidates may potentially save lives of many people from every corner of the globe.

References:
Klein E, Smith DL, Laxminarayan R (2007). "Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus, United States, 1999-2005." Emerg Infect Dis 13 (12): 1840-6